These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 34339789)
21. MCL-1 inhibitors - where are we now (2019)? Fletcher S Expert Opin Ther Pat; 2019 Nov; 29(11):909-919. PubMed ID: 31566022 [No Abstract] [Full Text] [Related]
22. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332 [TBL] [Abstract][Full Text] [Related]
23. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival. Eichhorn JM; Alford SE; Sakurikar N; Chambers TC Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425 [TBL] [Abstract][Full Text] [Related]
24. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. Bolomsky A; Vogler M; Köse MC; Heckman CA; Ehx G; Ludwig H; Caers J J Hematol Oncol; 2020 Dec; 13(1):173. PubMed ID: 33308268 [TBL] [Abstract][Full Text] [Related]
25. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides. Modi V; Sankararamakrishnan R J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820 [TBL] [Abstract][Full Text] [Related]
26. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells. Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900 [TBL] [Abstract][Full Text] [Related]
27. MiRNA-Mediated Knock-Down of Bcl-2 and Mcl-1 Increases Fludarabine-Sensitivity in CLL-CII Cells. Ashofteh N; Amini R; Molaee N; Karami H; Baazm M Asian Pac J Cancer Prev; 2021 Jul; 22(7):2191-2198. PubMed ID: 34319043 [TBL] [Abstract][Full Text] [Related]
28. Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members. Opferman JT FEBS J; 2016 Jul; 283(14):2661-75. PubMed ID: 26293580 [TBL] [Abstract][Full Text] [Related]
29. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML. Ewald L; Dittmann J; Vogler M; Fulda S Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941 [TBL] [Abstract][Full Text] [Related]
30. Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy. Yamaguchi R; Lartigue L; Perkins G Pharmacol Ther; 2019 Mar; 195():13-20. PubMed ID: 30347215 [TBL] [Abstract][Full Text] [Related]
31. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling. Grundy M; Seedhouse C; Jones T; Elmi L; Hall M; Graham A; Russell N; Pallis M PLoS One; 2018; 13(1):e0190682. PubMed ID: 29298347 [TBL] [Abstract][Full Text] [Related]
32. Small molecule Mcl-1 inhibitors for the treatment of cancer. Belmar J; Fesik SW Pharmacol Ther; 2015 Jan; 145():76-84. PubMed ID: 25172548 [TBL] [Abstract][Full Text] [Related]
33. The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737. Boiani M; Daniel C; Liu X; Hogarty MD; Marnett LJ J Biol Chem; 2013 Mar; 288(10):6980-90. PubMed ID: 23341456 [TBL] [Abstract][Full Text] [Related]
34. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling. Peperzak V; Slinger E; Ter Burg J; Eldering E Cell Death Differ; 2017 Jan; 24(1):111-119. PubMed ID: 27689871 [TBL] [Abstract][Full Text] [Related]
35. DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex. Nakajima W; Sharma K; Lee JY; Maxim NT; Hicks MA; Vu TT; Luu A; Yeudall WA; Tanaka N; Harada H Oncotarget; 2016 Jun; 7(24):36353-36365. PubMed ID: 27166195 [TBL] [Abstract][Full Text] [Related]
36. Targeting Mcl-1 for the therapy of cancer. Quinn BA; Dash R; Azab B; Sarkar S; Das SK; Kumar S; Oyesanya RA; Dasgupta S; Dent P; Grant S; Rahmani M; Curiel DT; Dmitriev I; Hedvat M; Wei J; Wu B; Stebbins JL; Reed JC; Pellecchia M; Sarkar D; Fisher PB Expert Opin Investig Drugs; 2011 Oct; 20(10):1397-411. PubMed ID: 21851287 [TBL] [Abstract][Full Text] [Related]
37. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML. Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848 [TBL] [Abstract][Full Text] [Related]
38. The carboxyl-terminal tail of Noxa protein regulates the stability of Noxa and Mcl-1. Pang X; Zhang J; Lopez H; Wang Y; Li W; O'Neill KL; Evans JJ; George NM; Long J; Chen Y; Luo X J Biol Chem; 2014 Jun; 289(25):17802-11. PubMed ID: 24811167 [TBL] [Abstract][Full Text] [Related]
39. Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer. Nakajima W; Hicks MA; Tanaka N; Krystal GW; Harada H Cell Death Dis; 2014 Feb; 5(2):e1052. PubMed ID: 24525728 [TBL] [Abstract][Full Text] [Related]
40. Mouse Noxa uses only the C-terminal BH3-domain to inactivate Mcl-1. Weber A; Ausländer D; Häcker G Apoptosis; 2013 Sep; 18(9):1093-105. PubMed ID: 23733106 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]